1984 was a good year. Contrary to orwellian predictions of doom it heralded a new era of confidence in the possibility of reducing the impact of coronary heart disease in the community. 
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The long term benefits of this procedure are limited because up to a third of the grafts will have become stenosed within a year of operation.'0 Fresh hope for these patients comes from the recently published Cholesterol Lowering Atherosclerosis Study (CLAS) in which 162 men who had had coronary bypass surgery were treated by a combination of diet, colestipol, and nicotinic acid in the expectation that their remaining coronary atherosclerotic lesions might be induced to regress.5 This treatment lowered low density lipoprotein cholesterol by 43% (from 4-42 to 2-51 mmol/l) and raised the high density lipoprotein concentration by 37%
(from 1-15 to 1-57 mmol/1), so that the ratio of total/ high density lipoprotein cholesterol was reduced almost to the value at which regression is the rule rather than the exception in animal studies. 8 An additional feature of the CLAS study was that benefit of treatment was evident across the whole range of plasma cholesterol values found at entry. Even patients who would be considered to have "normal" plasma cholesterol concentrations ( 
